These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 4801258)

  • 21. Improvement in mono-manual dexterity in parkinsonism when supplementing levodopa with an extracerebral decarboxylase inhibitor, RO 4-4602.
    Knutsson E; Mårtensson A
    Scand J Rehabil Med; 1974; 6(2):89-93. PubMed ID: 4837060
    [No Abstract]   [Full Text] [Related]  

  • 22. [Effect of carbidopa and L-dopa combination on the secretion of growth hormone in normal subjects and in patients with Parkinsonism].
    Nurzia A; Vacca U; Pirro R; Cerone G
    Clin Ter; 1975 Aug; 74(3):265-70. PubMed ID: 1227747
    [No Abstract]   [Full Text] [Related]  

  • 23. [Treatment of parkinsonism with L-dopa and an L-aromatic amino acid inhibitor].
    Streifler M; Vardi J; Kesten M
    Harefuah; 1972 Nov; 83(9):362-4. PubMed ID: 4669737
    [No Abstract]   [Full Text] [Related]  

  • 24. Effect of L-dihydroxyphenylalanine upon serum growth hormone concentrations in children and adolescents.
    Root AW; Russ RD
    J Pediatr; 1972 Oct; 81(4):808-13. PubMed ID: 5074361
    [No Abstract]   [Full Text] [Related]  

  • 25. [Somatotropin release after alpha-adrenergic stimulation in man].
    Massara F; Camanni F; Molinatti GM
    Folia Endocrinol; 1973 Dec; 26(6):476-82. PubMed ID: 4149508
    [No Abstract]   [Full Text] [Related]  

  • 26. Plasma testosterone content of male patients with Parkinson's disease during L-dopa treatment with or without dopadecarboxylase inhibitor.
    Pekkarinen A; Rinne UK; Salokangas R; Siirtola T; Sonninen V
    Acta Neurol Scand Suppl; 1972; 51():129-30. PubMed ID: 4514339
    [No Abstract]   [Full Text] [Related]  

  • 27. Cerebrospinal fluid monoamine metabolites and peripheral decarboxylase inhibitors in parkinsonism.
    Chase TN
    Neurology; 1970 Dec; 20(12):Suppl:36-40. PubMed ID: 5312403
    [No Abstract]   [Full Text] [Related]  

  • 28. Effects of L-dopa and chlorpromazine on human growth hormone and TSH secretion in normal subjects and acromegalics.
    Singh P; McDevitt DG; Mackay J; Hadden DR
    Horm Res; 1973; 4(5):293-301. PubMed ID: 4755420
    [No Abstract]   [Full Text] [Related]  

  • 29. [Therapy of Parkinson's syndrome with L-dopa only and in combination with a decarboxylase inhibitor. A comparison].
    Feise G; Paal G
    Nervenarzt; 1974 Mar; 45(3):126-32. PubMed ID: 4832035
    [No Abstract]   [Full Text] [Related]  

  • 30. Dissociation of growth hormone and prolactin secretion in Parkinson's disease following chronic L-dopa therapy.
    Malarkey WB; Cyrus J; Paulson GW
    J Clin Endocrinol Metab; 1974 Aug; 39(2):229-35. PubMed ID: 4371345
    [No Abstract]   [Full Text] [Related]  

  • 31. [Treatment of parkinsonism with L-Dopa associated with decarboxylase inhibitors. II].
    Gauthier G; de Ajuriaguerra J; Simona B; Constantinidis J; Eisenring JJ; Krassoievitch M; Yanniotis G; Tissot R
    Rev Neurol (Paris); 1970 Nov; 123(5):297-319. PubMed ID: 5513630
    [No Abstract]   [Full Text] [Related]  

  • 32. Endocrine function and glucose metabolism in patients with Parkinson's disease and their alternation by L-Dopa.
    Boyd AE; Lebovitz HE; Feldman JM
    J Clin Endocrinol Metab; 1971 Nov; 33(5):829-37. PubMed ID: 5125386
    [No Abstract]   [Full Text] [Related]  

  • 33. [Effect of intravenous injection of beta 1-24 corticotropin on somatotropin secretion].
    Thys C; Franchimont P
    C R Seances Soc Biol Fil; 1973; 167(11):1680-3. PubMed ID: 4371916
    [No Abstract]   [Full Text] [Related]  

  • 34. [Therapy of parkinsonian syndromes and plasmatic DOPA levels. Effects of L-DOPA and 3-OMD, administered alone or combined, with or without a decarboxylase inhibitor].
    Geissbühler F; Gaillard JM; Eisenring JJ; Krassoievitch M; Yanniotis G; Tissot R
    Rev Eur Etud Clin Biol; 1972 Jan; 17(1):38-44. PubMed ID: 5041348
    [No Abstract]   [Full Text] [Related]  

  • 35. [Effect of L-dopa on pituitary TSH and GH secretion in Parkinson's disease].
    Sakoda M; Kusaka T; Baba S; Shirakata S
    Nihon Naibunpi Gakkai Zasshi; 1972 Jul; 48(4):241-4. PubMed ID: 5066290
    [No Abstract]   [Full Text] [Related]  

  • 36. [Growth hormone stimulation with L. Dopa].
    Elkaïm R; Halimi S; Guidicelli C; Agnius-Delord C; Hadjian A; Perret J; Micoud M
    Nouv Presse Med; 1972 Mar; 1(10):675-7. PubMed ID: 4553974
    [No Abstract]   [Full Text] [Related]  

  • 37. [Effects of benserazide administration on prolactin secretion].
    Masturzo P; Murialdo G; Gallamini A; Nizzo MC; Magnani G
    Boll Soc Ital Biol Sper; 1978 Feb; 54(3):274-8. PubMed ID: 687436
    [No Abstract]   [Full Text] [Related]  

  • 38. Distribution of biogenic amines in the pituitary gland.
    Jacobowitz DM
    Prog Brain Res; 1973; 39():199-209. PubMed ID: 4597282
    [No Abstract]   [Full Text] [Related]  

  • 39. Potentiation and inhbition of some central actions of L(-)-dopa by decarboxylase inhibitors.
    Lotti VJ; Porter CC
    J Pharmacol Exp Ther; 1970 Apr; 172(2):406-15. PubMed ID: 5441162
    [No Abstract]   [Full Text] [Related]  

  • 40. Effect of L-dopa administration on growth hormone secretion in normal subjects and Parkinsonian patients.
    Cavagnini F; Peracchi M; Scotti G; Raggi U; Pontiroli AE; Bana R
    J Endocrinol; 1972 Sep; 54(3):425-33. PubMed ID: 5071365
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.